Loading
The confirmatory trial for the first c-MET ADC, which was approved early on response rate alone.
TeliMET NSCLC-01, trial NCT04928846 sponsored by AbbVie, is the randomised phase 3 confirmatory trial for telisotuzumab vedotin, the first c-MET antibody-drug conjugate, which received accelerated approval in May 2025 on response rate alone. It compares telisotuzumab vedotin with docetaxel in previously treated c-Met-overexpressing, EGFR-wild-type non-squamous non-small-cell lung cancer and plans to enrol 768 patients, with enrolment ongoing and no results available. The accelerated approval rested on the single-arm LUMINOSITY study, in which about a third of patients with high c-Met expression responded, and OnCo links the trial to MET as a target. Whether a response-rate approval converts into a survival advantage over chemotherapy is exactly what this trial exists to answer. Telisotuzumab vedotin has its own page.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, MET, Non-small-cell lung cancer.
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, MET, AbbVie (incl. ImmunoGen, Capstan).
Shares Telisotuzumab vedotin, MET exon 14 and MET-amplified non-small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Shares AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/